Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of T-1101 in Advanced Refractory Solid Tumors
NCT03349073Phase 1Completed
- Sponsor
- Taivex Therapeutics
- Start
- Sep 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of T-1101, sponsored by Taivex Therapeutics. Primary endpoint: Clinical Tumor Response of T-1101 (Tosylate) in Participants with Advanced Cancers up to 2 years. Started Sep 2017; status: completed.
02
Drugs
T-1101
Beyond the preview
Go deeper on NCT03349073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349073.